Date: 2016-12-05
Type of information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at the European Society for Medical Oncology (ESMO) 2016 Congress
Company: Noxxon Pharma (Germany)
Product: NOX-A12 (olaptesed pegol) with T cell and NK cell based therapies
Action
mechanism: cell therapy/spiegelmer. Olaptesed pegol/NOX-A12 specifically antagonizes CXCL12/SDF-1 (CXC Chemokine Ligand 12 / Stromal Cell-Derived Factor-1), a chemokine which attracts and activates immune and non-immune cells including stem cells from the bone marrow. CXCL12 binds with high affinity to two chemokine receptors, CXCR4 and CXCR7. The CXCL12 / CXCR4 / CXCR7 axis has been shown to play a role in stem cell mobilization, vasculogenesis, tumor growth and metastasis. CXCL12 signaling has been shown to play an important role in the pathophysiology of CLL, especially in the interaction of leukemic cells with the tissue microenvironment. The therapeutic concept of NOX-A12 is to inhibit such tumor-supporting interactions and thereby sensitize CLL cells to chemotherapy.
Disease:
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: * On December 5, 2016, Noxxon Pharma announced that it presented data at the ASH 2016 conference studying the role of CXCL12 inhibition by NOX-A12 (olaptesed pegol) on Natural Killer (NK) cells in tumor stroma spheroids, a preclinical model that mimics the complexity of the tumor microenvironment (CXCL12 Inhibition by NOX-A12 (Olaptesed Pegol) Synergizes With the ADCC Activity of CD20 Antibodies by Increasing NK Cell Infiltration in a 3D Lymphoma Model. Dirk Zboralski, Anna Kruschinski, Dirk Eulberg and Axel Vater.) These studies showed that NOX-A12 synergizes with NK cell mediated antibody-dependent cellular cytotoxicity (ADCC). * On October 10, 2016, Noxxon Pharma announced that it presented data at the ESMO 2016 conference in Copenhagen, Denmark, studying the role of CXCL12 inhibition by NOX-A12 (olaptesed pegol) in tumor stroma spheroids (CXCL12 Inhibition with NOX-A12 (Olaptesed Pegol) Increases T and NK Cell Infiltration and Synergizes with Immune Checkpoint Blockade and ADCC in Tumour-Stroma Spheroids. Dirk Zboralski, Anna Kruschinski, Dirk Eulberg and Axel Vater). These studies showed that NOX-A12 synergizes with therapies working through either T cells or NK cells. Further studies of NOX-A12 with agents working through T cells such as checkpoint inhibitors or CAR-T cells as well as NK cell-based therapies are warranted.
